Journal of hypertension · 2025
Reclassification of patients with normal blood pressure levels after 2024 European society of cardiology guidelines on hypertension.
СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tocci Giuliano, Nardoianni Giulia, Pala Barbara, Citoni Barbara, Virdis Agostino, Muiesan Maria Lorenza, Grassi Guido, Barbato Emanuele, Volpe Massimo
Аннотация
INTRODUCTION: In 2024, the European Society of Cardiology (ESC) guidelines proposed a new classification of elevated blood pressure (BP) and hypertension.
AIM: To evaluate how many individuals with optimal, normal, and high-normal BP, as defined by the 2023 European Society of Hypertension (ESH) guidelines, would be reclassified as not-elevated or elevated BP, according to the new ESC guidelines.
METHODS: In this single-center, observational, retrospective, cohort study, we included adult individuals who were consecutively evaluated for home, office, and ambulatory BP measurements, and global cardiovascular risk stratification. All patients underwent BP measurements using a validated, oscillometric, automatic device (Mobil-O-Graph PWA Monitor, I.E.M. GmbH, Stolberg, Germany). Only untreated individuals with office BP levels <140/<90 mmHg and without comorbidities were considered for the analysis. Selected population was stratified according to 2023 ESH (optimal BP, <120/<80 mmHg; normal BP, 120-129/80-84 mmHg; high-normal BP, 130-139/85-89 mmHg) and then reclassified according to 2024 ESC guidelines (not-elevated BP, <120/<70 mmHg; elevated BP, 120-139/70-89 mmHg). Home and 24-h ambulatory BP levels were also evaluated in each category, when available.
RESULTS: We analysed 1230 adult untreated individuals with valid office BP levels, among whom 89.0% also had ambulatory and 42.6% home BP data, respectively. According to 2023 ESH guidelines, 262 (21.3%) individuals had optimal, 375 (30.5%) normal, and 593 (48.2%) high-normal BP levels; according to 2024 ESC guidelines, 87 (7.1%) had nonelevated, and 1143 (92.9%) had elevated BP. Compared to 2023 ESH guidelines, 66.8% individuals with optimal BP, and all individuals (100.0%) with normal and high-normal BP levels were reclassified as elevated BP by adopting 2024 ESC guidelines. This shift is more evident in women than in men (67.2 vs. 65.8%; P < 0.001).
CONCLUSION: According to 2024 ESC guidelines, most individuals with optimal, and all those with normal and high-normal BP levels, as defined by 2023 ESH guidelines, are reclassified in the elevated BP category.
AIM: To evaluate how many individuals with optimal, normal, and high-normal BP, as defined by the 2023 European Society of Hypertension (ESH) guidelines, would be reclassified as not-elevated or elevated BP, according to the new ESC guidelines.
METHODS: In this single-center, observational, retrospective, cohort study, we included adult individuals who were consecutively evaluated for home, office, and ambulatory BP measurements, and global cardiovascular risk stratification. All patients underwent BP measurements using a validated, oscillometric, automatic device (Mobil-O-Graph PWA Monitor, I.E.M. GmbH, Stolberg, Germany). Only untreated individuals with office BP levels <140/<90 mmHg and without comorbidities were considered for the analysis. Selected population was stratified according to 2023 ESH (optimal BP, <120/<80 mmHg; normal BP, 120-129/80-84 mmHg; high-normal BP, 130-139/85-89 mmHg) and then reclassified according to 2024 ESC guidelines (not-elevated BP, <120/<70 mmHg; elevated BP, 120-139/70-89 mmHg). Home and 24-h ambulatory BP levels were also evaluated in each category, when available.
RESULTS: We analysed 1230 adult untreated individuals with valid office BP levels, among whom 89.0% also had ambulatory and 42.6% home BP data, respectively. According to 2023 ESH guidelines, 262 (21.3%) individuals had optimal, 375 (30.5%) normal, and 593 (48.2%) high-normal BP levels; according to 2024 ESC guidelines, 87 (7.1%) had nonelevated, and 1143 (92.9%) had elevated BP. Compared to 2023 ESH guidelines, 66.8% individuals with optimal BP, and all individuals (100.0%) with normal and high-normal BP levels were reclassified as elevated BP by adopting 2024 ESC guidelines. This shift is more evident in women than in men (67.2 vs. 65.8%; P < 0.001).
CONCLUSION: According to 2024 ESC guidelines, most individuals with optimal, and all those with normal and high-normal BP levels, as defined by 2023 ESH guidelines, are reclassified in the elevated BP category.